Skip to main content
Premium Trial:

Request an Annual Quote

MediGene Licenses Gene Regulation System From Valentis

NEW YORK, May 20-Valentis said today that it has licensed its GeneSwitch gene regulation technology to the German drug developer MediGene.

 

MediGene will have the rights to use this technology for research purposes, in exchange for an immediate payment and annual maintenance fees.

 

The companies did not disclose financial details of the agreement.

 

Valentis' technology allows researchers to regulate the expression of certain genes in transgenic animals and cell cultures, a process useful in gene function identification and target validation.


This is the sixth non-exclusive license that the Burlingame, Calif.-based company has granted to pharmaceutical and biotechnology partners since February 2001.

 

MediGene, a publicly traded company that focuses on cancer drug development, is based in Martinsreid, with a U.S. subsidiary in San Diego, Calif.

 

For additional information about the deal, click here.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.